NORWOOD, Mass., Sept. 26, 2022 /PRNewswire/ -- Corbus
Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the
"Company"), an immunology company, today announced the appointment
of Anne Altmeyer, PhD, MBA, MPH to
its board of directors.
"Anne is a dynamic leader with a proven track record of
advancing R&D programs and creating corporate value through
successful business development transactions," said Alan Holmer, Chairman of the Board of Directors
of Corbus. "Her corporate development expertise and oncology
R&D experience will be invaluable to Corbus as we advance and
expand our pipeline. We are excited to welcome Anne to our
board."
Dr. Altmeyer is currently the President and CEO of TigaTx, Inc.
She previously served as the Chief Business Officer of Sigilon
Therapeutics and Adicet Bio. Dr. Altmeyer also held roles of
increasing responsibility in corporate development and program
management over 15 years across large pharmaceutical organizations.
Specifically, Dr. Altmeyer served as Vice President in Global
Business Development at Baxalta and Vice President in Oncology
Business Development and Companion Diagnostics at Novartis. Dr.
Altmeyer began her industry career in program management roles at
Merck & Company. She received her PhD from the University Louis
Pasteur, Strasbourg, France, and
did her postdoctoral fellowships at New York
University and Cornell
University Medical College in New
York City. She also has an MBA from Rutgers University and a Masters in Public Health
from the Robert Wood Johnson Medical School, in New Jersey.
Dr. Altmeyer said, "I am honored to join the Corbus Board and I
look forward to working with the Corbus Team and the Board toward
advancing the mission of developing new immune-oncology
therapeutics for cancer patients." Yuval
Cohen, Chief Executive Officer of Corbus added, "Having Anne
join us provides Corbus with a valuable resource. Her decades of
experience in oncology drug development and business strategy will
help guide Corbus through the execution of our expanding pipeline
and the partnerships we will need to establish to do so."
About Corbus
Corbus is an immunology company committed to helping people
defeat serious illness by bringing innovative scientific approaches
to well understood biological pathways. Corbus' current
pipeline includes anti-integrin monoclonal antibodies that block
activation of TGFβ and small molecules that activate or inhibit the
endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts. For more information
on Corbus, visit corbuspharma.com. Connect with us on Twitter,
LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and Private
Securities Litigation Reform Act, as amended, including those
relating to the Company's restructuring, trial results, product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of forward-looking
expressions, including, but not limited to, "expect," "anticipate,"
"intend," "plan," "believe," "estimate," "potential," "predict,"
"project," "should," "would" and similar expressions and the
negatives of those terms. These statements relate to future events
or our financial performance and involve known and unknown risks,
uncertainties, and other factors, including the potential impact of
the recent COVID-19 pandemic and the potential impact of sustained
social distancing efforts, on our operations, clinical development
plans and timelines, which may cause actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Such factors include those set forth in
the Company's filings with the Securities and Exchange Commission.
Prospective investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this press release. The Company undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
INVESTOR CONTACT:
Sean Moran
smoran@corbuspharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/corbus-pharmaceuticals-appoints-anne-altmeyer-phd-to-board-of-directors-301632584.html
SOURCE Corbus Pharmaceuticals